These include issues of informed consent that are the focus of this "points to consider" document.
The types of information derived from genome sequencing will be both health (current and future) and non-health related. In addition to information specific to clinical indications for testing on a GS/ES platform, they include: gene-variant carrier status that may have implications for reproductive decision making; information about disease susceptibility or predisposition; information about ancestry, which is currently mostly informational but that may in time have clinical utility; and diagnosis of unsuspected disorders. Some phenotypes may allow narrow targeting, and others (e.g., intellectual disability or autism spectrum disorder) may leave the majority of the exome open for testing. Current technologies are being applied in both the postnatal and prenatal settings as well as to somatic and germ-line conditions. In some cases, incidental findings can be as important to a family as they are to the individual.
The following are recommendations regarding the informed consent that should be obtained before clinical applications of GS/ES for germ-line testing. Particular focus is placed on situations in which the laboratory and physician may be presented with information apparently unrelated to genes known to be associated with the phenotype that led to testing. These points reiterate some prior ACMG positions on this topic.
1. Before initiating GS/ES, counseling should be performed by a medical geneticist or an affiliated genetic counselor and should include written documentation of consent from the patient. 2. Incidental/secondary findings revealed in either children or adults may have high clinical significance for which interventions exist to prevent or ameliorate disease severity. Patients should be informed of this possibility as a part of the informed consent process. 3. Pretest counseling should include a discussion of the expected outcomes of testing, the likelihood and type of incidental results that may be generated, and the types of results that will or will not be returned. Patients should know if and what type of incidental findings may be returned to their referring physician by the laboratory performing the test. 4. Patients should be counseled regarding the potential benefits and risks of GS/ES, the limitations of such testing, potential implications for family members, and alternatives to such testing. 5. GS/ES is not recommended before the legal age of majority except for: a. Phenotype-driven clinical diagnostic uses; b. Circumstances in which early monitoring or interventions are available and effective; or c. Institutional review board-approved research. 6. As part of the pretest counseling, a clear distinction should be made between clinical and research-based testing. 7. Patients should be informed as to whether individually identifiable results may be provided to databases, and they should be permitted to opt out of such disclosure.
